Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease

This study has been completed.
Information provided by:
Bristol-Myers Squibb Identifier:
First received: September 13, 2007
Last updated: April 12, 2011
Last verified: April 2011

September 13, 2007
April 12, 2011
December 2002
March 2005   (final data collection date for primary outcome measure)
  • serum LDL-C [ Time Frame: at week 12 ]
  • ALT value
Same as current
Complete list of historical versions of study NCT00529178 on Archive Site
  • change in HDL-C, TC and TG [ Time Frame: at week 12 ]
  • clinical symptoms related to acute hepatic injury
Same as current
Not Provided
Not Provided
Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease
A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Study to Determine the Efficacy and Safety of Pravastatin 80 mg Administered Once Daily to Hypercholesterolemic Subjects With Chronic, Well Compensated Liver Disease
To determine in hypercholesterolemic subjects with chronic, well-compensated liver disease, the percent change from baseline to Week 12 in serum LDL-C of pravastatin 80 mg compared to placebo.
Not Provided
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Drug: Pravastatin
Not Provided
Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R; Pravastatin in Chronic Liver Disease Study Investigators.. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007 Nov;46(5):1453-63.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2005
March 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Chronic, well-compensated stable liver
  • Hypercholesterolemia

Exclusion Criteria:

  • Signs or symptoms of ascites, jaundice, or cirrhosis with a Child-Pugh Score > 5
  • History of disorders affecting serum bilirubin levels, more than 1 chronic liver disease, significant endocrine, renal, or gastrointestinal disease, or uncontrolled hypertension
  • Treatment with lipid-lowering drugs, unless they have been withdrawn within the timeframe specified in the protocol
18 Years to 80 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Bristol-Myers Squibb
Not Provided
Not Provided
Bristol-Myers Squibb
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP